Neurobo Pharmaceuticals Inc
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has com… Read more
Neurobo Pharmaceuticals Inc (NRBO) - Total Assets
Latest total assets as of September 2024: $22.15 Million USD
Based on the latest financial reports, Neurobo Pharmaceuticals Inc (NRBO) holds total assets worth $22.15 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neurobo Pharmaceuticals Inc - Total Assets Trend (2014–2023)
This chart illustrates how Neurobo Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neurobo Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Neurobo Pharmaceuticals Inc's total assets of $22.15 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2023)
This chart illustrates how Neurobo Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurobo Pharmaceuticals Inc's current assets represent 98.8% of total assets in 2023, an increase from 94.8% in 2014.
- Cash Position: Cash and equivalents constituted 98.5% of total assets in 2023, up from 91.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Neurobo Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Neurobo Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Neurobo Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Neurobo Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neurobo Pharmaceuticals Inc is currently not profitable relative to its asset base.
Neurobo Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.41 | 5.54 | 6.78 |
| Quick Ratio | 2.41 | 5.54 | 6.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.82 Million | $ 21.42 Million | $ 12.04 Million |
Neurobo Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Neurobo Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.32 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -32.1% |
| Total Assets | $22.78 Million |
| Market Capitalization | $4.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neurobo Pharmaceuticals Inc's assets below their book value (0.18 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Neurobo Pharmaceuticals Inc's assets decreased by 32.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neurobo Pharmaceuticals Inc (2014–2023)
The table below shows the annual total assets of Neurobo Pharmaceuticals Inc from 2014 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $22.78 Million | -32.07% |
| 2022-12-31 | $33.53 Million | +99.62% |
| 2021-12-31 | $16.80 Million | +53.16% |
| 2020-12-31 | $10.97 Million | -24.19% |
| 2019-12-31 | $14.47 Million | -26.54% |
| 2018-12-31 | $19.69 Million | +3.56% |
| 2017-12-31 | $19.02 Million | -23.18% |
| 2016-12-31 | $24.75 Million | +450.09% |
| 2015-12-31 | $4.50 Million | +1193.10% |
| 2014-12-31 | $348.00K | -- |